Last reviewed · How we verify
Nicotinamide Mononucleotide
At a glance
| Generic name | Nicotinamide Mononucleotide |
|---|---|
| Sponsor | Abinopharm, Inc |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of NMN Supplementation on Organ System Biology (NA)
- PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS) (NA)
- Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults (NA)
- Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery (PHASE2)
- Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue (NA)
- Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (PHASE2)
- Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome (NA)
- A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nicotinamide Mononucleotide CI brief — competitive landscape report
- Nicotinamide Mononucleotide updates RSS · CI watch RSS
- Abinopharm, Inc portfolio CI